Numerous studies have increasingly focused on exploring the molecular biomarkers of LCA, however, despite the identification of some potential molecular targets such as TLSs, NOTCH1, and BMP2, new effective therapeutic targets for LCA have not yet been confirmed (9–11). The gene discussed is NOTCH1; the disease is Leber congenital amaurosis.